Skip to content
Screener

Arbutus Biopharma Corporation ABUS EV / EBITDA

EV / EBITDA at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
27.4×—
Gilead Sciences logo
Gilead SciencesGILD
17.5×-0.7×
ALN
Alnylam PharmaceuticalsALNY
36.7×—
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
32.6×—
AbbVie logo
AbbVieABBV
19.8×—
Lantheus Holdings logo
Lantheus HoldingsLNTH
18.6×+7.5×

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Cash & equivalents$23.7M-36.1%
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$896.82M+42.4%
Enterprise value$873.75M+47.1%
P/E5.6×—
P/S4.7×-36.1×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Calculated from Arbutus Biopharma Corporation’s reported figures.

enterprise value/ebitda=5.5×

Based on the most recent quarter.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 7:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001447028-26-000021

FAQ

What is Arbutus Biopharma Corporation's EV / EBITDA?
Arbutus Biopharma Corporation (ABUS) reported EV / EBITDA of 5.5× in Q1 2026.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Arbutus Biopharma Corporation's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude